Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus
Statin therapy modestly increases new-onset diabetes risk. The effect of PCSK9 inhibition on new-onset diabetes, glycemia and weight remains unclear.We studied the effects of the PCSK9 inhibitor evolocumab on fasting plasma glucose [FPG], glycated hemoglobin (HbA1c), weight and new-onset diabetes me...
Main Authors: | Sattar, N, Toth, P, Blom, D, Koren, M, Soran, H, Uhart, M, Elliott, M, Cyrille, M, Somaratne, R, Preiss, D |
---|---|
Format: | Journal article |
Published: |
Elsevier
2017
|
Similar Items
-
Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia
by: Yanren Peng, et al.
Published: (2022-03-01) -
Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
by: Qingyu Wu, et al.
Published: (2022-11-01) -
ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01) -
ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01) -
Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
by: Bianca E. Suur, et al.
Published: (2022-09-01)